



A Premium Solution to Promote Calcium Absorption and Bone Health

Bidirectional Regulator of Calcium and Phosphorus
Patent No. PCT/CN2020/098771



What is EuBone™

EuBone™ is a specially formulated botanical blend with three traditional Asian herbs: *Eucommia ulmoides*, *Drynaria fortunei* and *Cuscuta chinensis*.

Applications

Supported Forms: Capsules and Tablets, can be used alone or with collagen, vitamins and minerals to improve the absorption of minerals

Dosage: 500-1000 mg/day

Applicable to: Individuals over 40 years old with osteoporosis or low bone mass and postmenopausal women



Supports Healthy
Bone Functions



Improves Calcium
Absorption



Reduces Fracture
Risk



Improves Bone Strength,
Bone Density, and Bone Elasticity


Why Choose EuBone™

- Multi-Model Animal Trials Confirm the Safety and Effectiveness of EuBone™
- Bidirectionally Regulates the Balance of Osteoblasts and Osteoclasts
- Clear Mechanism and Target to Help Promote Serum Calcium and Phosphorus Regulation


Animal Trial

EuBone™ can improve the content of calcium and phosphorus in the blood of osteoporotic model rats by reducing the content of calcium and phosphorus in urine, thereby effectively regulating the balance of calcium and phosphorus to reduce the loss of minerals.

EuBone™ increases the concentration of Ca&P




EuBone™ decreases the concentration of Ca&P




EuBone™ can significantly improve the bone microstructure of osteoporotic model rats, increase bone density, bone strength, bone elasticity and reduce the risk of fracture.


EuBone™ increases bone strength (N)




EuBone™ increases BMD (g/cm³)



EuBone™ increases bone elasticity (N)



3D-microCT images



Product Stability

Two-year shelf life if stored under cool, dry and dark conditions

Our Customized Service also Includes:

- Contract Manufacturing for Finished Product and Botanical Extraction
- Formulation Design
- Functionality Evaluation

*Our clinical trial is ongoing and scheduled to be completed by the end of 2021.